Citations

Clear

6055 citation(s) found for "Vu, Peter".

Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric, Version 3.2024, NCCN Clinical Practice Guidelines In Oncology
Gupta, Samir , Axell, Lisen, Burke, Carol A. , Chen, Lee-may, Chung, Daniel C. , Clayback, Katherine M, Felder, Seth , Giardiello, Francis M., Gustafson, Susan, Hagemann, Andrea R. , Hall, Michael J. , Idos, Gregory , Joseph, Nora, Kassem, Nawal , Kelly, Kaitlyn, Kieber‐Emmons, AnnMarie, Kupfer, Sonia S., Lang, Katie, Llor, Xavier , Markowitz, Arnold J. , Prats, Mariana Moreno, Niell‐Swiller, Mariana, Pirzadeh‐Miller, Sara , Samadder, N. Jewel , Shibata, David , Swanson, Benjamin , Szymaniak, Brittany M. , Welborn, Jeanna, Wiesner, Georgia L. , Yurgelun, Matthew B. , Dwyer, Mary A., Darlow, Susan, Diwan, Zeenat, Samadder, Niloy Jewel, Gupta, Samir , Burke, Carol A , Hodan, Rachel , Weiss, Jennifer M. , Chung, Daniel C., Foda, Zachariah H. , Grady, William M. , Hampel, Heather , Katona, Bryson W , Outlaw, Darryl Alan , Stanich, Peter P.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | December 16, 2024 | Volume: 22 | Issue: 10 | Pages: 695-711

10.6004/jnccn.2024.0061 | PMID 39689429 Get It

Multigene panel testing has allowed for the detection of a growing number of inherited pathogenic/likely pathogenic variants in people at high risk of cancer, including endometrial cancer (EC). Hereditary syndromes associated with EC include Lynch syndrome, PTEN hamartoma tumor syndrome, and Peutz-Jeghers syndrome. This manuscript provides the latest recommendations from the NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric on the screening and management of EC in patients at high risk for these syndromes, as well as the advantages and limitations of multigene panel testing. This manuscript also describes recent updates to these guidelines regarding de-implementation of colon cancer screening in individuals with CHEK2 pathogenic/likely pathogenic variants, based on the most up-to-date evidence regarding the association between CHEK2 pathogenic/likely pathogenic variants and colon cancer risk.
Which Osteochondritis Dissecans Lesions Will Heal Nonoperatively? An Application of Machine Learning to the ROCK Prospective Cohort
Johnstone, T, Espiritu, Joseph , Tompkins, Marc , Milewski, Matthew D. , Nissen, Carl W. , Shea, Kevin G. , Group:, the ROCK, Egger, Anthony C. , Anderson, Christian N. , Pace, James Lee, Polousky, John D. , Ellemann, Jutta, Meenen, N. M., Ellis, Henry B. , Carey, James, Nissen, Carl , Espiritu, Joseph, Group:, the ROCK, Nelson, Bradley J. , Pace, James Lee, Edmonds, Eric W. , Fabricant, Peter D , Krych, Aaron J. , Myer, Gregory D. , Kocher, Mininder Singh , Carey, James

Mayo Clinic

Orthopaedic Journal of Sports Medicine | December 16, 2024 | Volume: 12 | Issue: 12 | Pages: No page available

10.1177/23259671241297145 | PMID 39697601 Get It

Background: There are limited evidence-based guidelines to predict which osteochondritis dissecans (OCD) lesions will heal with nonoperative treatment. Purpose: To train a set of classification algorithms to predict nonoperative OCD healing while identifying new clinically meaningful predictors. Study Design: Case-control study; Level of evidence, 3. Methods: Patients with OCD of the knee with open physes undergoing nonoperative management were prospectively queried from the Research on OCD of the Knee (ROCK) cohort ( https://kneeocd.org ) in April 2022. Patients were included if they met the study criteria for nonoperative treatment success or failure. Nonoperative treatment success was defined as complete healing on magnetic resonance imaging (MRI) and total return to sports participation. Failure was defined as the crossover from nonoperative management to surgery at any point at or beyond the 3-month follow-up. If a patient did not meet one of these criteria, they were not included. Normalized lesion size, lesion location, patient characteristics, and symptoms were used as clinically relevant predictors. Results: A total of 64 patients were included, of whom 24 (37.5%) patients successfully healed with nonoperative management. Multivariate logistic regression revealed that a 1% increase in normalized lesion width was associated with an increase in the likelihood of nonoperative failure (odds ratio [OR], 1.41 [95% CI, 1.17-1.81]; P < .01). By contrast, lesions in the posterior sagittal zone (OR, 0.08 [95% CI, 0.009-0.43]; P < .01) or the medial-most coronal zone (for lesions of the medial femoral) and lateral-most coronal zone (for lesions of the lateral femoral condyle) on MRI (OR, 0.05 [95% CI, 0.004-0.44]; P < .01) were associated with a decrease in the likelihood of nonoperative treatment failure. Support vector machines had a cross-validated area under the receiver operating characteristic curve of 0.89 and a classification accuracy of 83.3%. Conclusion: Lesion location in the posterior aspect of the condyle on sagittal MRI and lesion location in the medial-most or lateral-most locations on coronal MRI were identified as statistically significant predictors of increased nonoperative treatment success on multivariate analysis. Machine learning models can predict which OCD lesions will heal with nonoperative management with superior accuracy compared with previously published models.
Menopausal hormone therapy: assessing associations with breast and colorectal cancers by familial risk
Milne, Roger L. , John, Esther M. , Andrulis, Irene L., Colonna, Sarah V. , Phillips, Kelly‐Anne , Investigators, kConFab, Marchand, Loı̈c Le , Phipps, Amanda I. , Schmit, Stephanie L. , Gallinger, Steven , Pai, Rish K. , Samadder, N. Jewel , Thorne, Heather , Maclnnis, Robert , Jenkins, Mark A , Milne, Roger L , John, Esther M , Andrulis, Irene L , Colonna, Sarah V , Phillips, Kelly-Anne , Marchand, Loïc Le , Schmit, Stephanie L , Macrae, Finlay A , Buchanan, Daniel D , Gallinger, Steven , Pai, R K , Samadder, N Jewel , Giles, Graham G , Southey, Melissa C , Hopper, John L. , Terry, Mary Beth , MacInnis, Robert J. , Jenkins, Mark A. , Daly, Mary Beryl , Investigators, kConFab, Newcomb, Polly A. , Macrae, Finlay , Buchanan, Daniel D. , Giles, Graham G. , Southey, Melissa C. , Hopper, John L. , Terry, Mary Beth

Mayo Clinic

JNCI Cancer Spectrum | December 14, 2024 | Volume: 9 | Issue: 1 | Pages: No page available

10.1093/jncics/pkae121 | PMID 39673461 Get It

Abstract Menopausal users of hormone replacement therapy (HRT) are at increased breast cancer risk and decreased colorectal cancer (CRC) risk compared with individuals who have never used HRT, but these opposing associations may differ by familial risk of breast cancer and CRC. We harmonized data from 3 cohorts and generated separate breast cancer and CRC familial risk scores based on cancer family history. We defined moderate or strong family history as a risk score of 0.4 or higher, where 0.4 was equivalent to a 50-year-old woman with 1 parent diagnosed with either breast cancer or CRC at 55 years of age. Of 24 486 women assessed, 1243 and 405 were diagnosed with incident breast cancer and CRC, respectively. For breast cancer, menopausal HRT ever use versus never use hazard ratios were 1.27 (95% CI = 1.11 to 1.45) for a breast cancer familial risk score below 0.4 and 1.01 (95% CI = 0.82 to 1.25) for a breast cancer familial risk score of 0.4 or higher (Pdifference = .08). For CRC, menopausal HRT hazard ratios were 0.63 (95% CI = 0.50 to 0.78) for a CRC familial risk score below 0.4 and 1.21 (95% CI = 0.73 to 2.00) for a CRC familial risk score of 0.4 or higher (Pdifference = .03). Associations with menopausal HRT use that apply to the general population may not hold for women at moderate or strong familial risk of these cancers.
An international Delphi consensus on patient preparation for metabolic and bariatric surgery
Clyde, Danielle , Adib, Reza, Baig, Sarfaraz Jalil , Bhasker, Aparna Govil , Catalain, Copaescu, Clare, Ken , Beaux, Andrew de, Drummond, Gillian, Fawal, Hayssam, Ghanem, Omar M. , Hopkins, George, Kothari, Shanu N. , Kow, Lilian , Faria, Sílvia Leite , Madhok, Brij, Mahon, David, Miller, Karl , Nimeri, Abdelrahman , O’Kane, Mary , Poggi, Luis , Saliminen, Paulina, Sarkar, Rupa , Shenfine, Jon, Sogg, Stephanie , Suter, Michel , Taha, Safwan , Tahrani, Abd A. , Voon, Kelvin , Welbourn, Richard , Lamb, Peter , Mahawar, Kamal , Yang, Wah , Salminen, Paulina , Kermansaravi, Mohammad , Zerrweck, Carlos , Yang, Wah , Byrne, James Patrick , Cameron, David, Fried, Martin , Graham, Yitka N. H. , Goel, Ramen , Husain, Farah Anwari , Joyce, Brian, Miras, Alexander Dimitri , Moussa, Osama , Neto, Manoel Galvão , Parmar, Chetan D. , Peterli, Ralph , Stenberg, Erik , Vilallonga, Ramón , Robertson, Andrew G.

Mayo Clinic

Clinical Obesity | December 14, 2024 | Volume: 15 | Issue: 2 | Pages: No page available

10.1111/cob.12722 | PMID 39673462 Get It

SummaryGlobal obesity rates have risen dramatically, now exceeding deaths from starvation. Metabolic and bariatric surgery (MBS), initially for severe obesity (BMI ≥35 kg/m2), is performed globally over 500 000 times annually, offering significant metabolic benefits beyond weight loss. However, varying eligibility criteria globally impact patient care and healthcare resources. Updated in 2022, ASMBS and IFSO guidelines aim to standardise MBS indications, reflecting current understanding and emphasising comprehensive preoperative assessments. Yet, clinical variability persists, necessitating consensus‐based recommendations. This modified Delphi study engaged 45 global experts to establish consensus on perioperative management in MBS. Experts selected from bariatric societies possessed expertise in MBS and participated in a two‐round Delphi protocol. Consensus was achieved on 90 of 169 statements (53.3%), encompassing multidisciplinary team composition, patient selection criteria, preoperative testing, and referral pathways. The agreement highlighted the critical role of comprehensive preoperative assessments and the integration of healthcare professionals in MBS. These findings offer essential insights to standardise perioperative practices and advocate for evidence‐based guidelines in MBS globally. The study underscores the need for unified protocols to optimise outcomes and guide future research in MBS.
Making Sense of ‘Porto‐Sinusoidal Vascular Disorder’: What Does It Mean for the Pathologist and the Patient?
Gouw, Annette S.H. , Callea, Francesco , Dienes, Hans‐Peter, Goodman, Zachary , Kakar, Sanjay , Kleiner, David E. , Lackner, Carolin , Park, Young Nyun , Roberts, Eve A., Schirmacher, Peter , Terracciano, Luigi , Wanless, Ian R., Zen, Yoh , Kleiner, David Erwin , Park, Young Nyun , Tiniakos, Dina , Zen, Yoh , Burt, Alastair D , Clouston, Andrew Donald , Kakar, Sanjay , Torbenson, Michael , Weber, Achim

Mayo Clinic

Liver International | December 12, 2024 | Volume: 45 | Issue: 1 | Pages: No page available

10.1111/liv.16196 | PMID 39665793 Get It

Comparison of pulmonary and aortic root and cusp dimensions in normal adults using computed tomography: potential implications for Ross procedure planning
Jelenc, Matija , Jelenc, Blaž , Habjan, Sara, Fries, Peter , Schäfers, Hans Joachim, Abeln, Karen B. , Michelena, Héctor I. , Schäfers, Hans‐Joachim

Mayo Clinic

Interdisciplinary CardioVascular and Thoracic Surgery | December 11, 2024 | Volume: 39 | Issue: 6 | Pages: No page available

10.1093/icvts/ivae206 | PMID 39657909 Get It

Abstract OBJECTIVES The Ross procedure is currently receiving renewed interest. Its function and durability depend on preservation of pulmonary valve anatomy; limited data exist on normal pulmonary valve geometry. The objective was to compare aortic and pulmonary root and cusp dimensions in adults with normal tricuspid aortic and pulmonary valves. METHODS We reviewed 507 coronary computed tomography studies, selecting those with adequate visibility of both pulmonary and aortic roots for further analysis. Diastolic aortic and pulmonary root and cusp dimensions were measured. Root dimensions at different phases of the cardiac cycle were measured in 3 patients. RESULTS We analysed studies of 50 patients with the mean age of 54 years [standard deviation (SD): 16]. In end-diastole, pulmonary root had a smaller sinutubular to basal ring ratio than the aortic root [0.82 (SD: 0.09) vs 1.14 (SD: 0.12), P &lt; 0.001]. Aortic and pulmonary cusps had similar dimensions; however, pulmonary cusp effective height was lower [5.9 mm (SD: 1.6) vs 8.4 mm (SD: 1.2), P &lt; 0.001]. Pulmonary basal ring perimeter was largest at end-diastole and smallest at end-systole, with the relative difference of 23.5% (SD: 2.7). CONCLUSIONS The pulmonary root has a similar cusp size compared to the aortic root, but a different shape, resulting in a lower pulmonary cusp effective height. The perimeter of the pulmonary basal ring changes during the cardiac cycle. These findings suggest that stabilizing the autograft to normal aortic, rather than pulmonary, root dimensions should result in normal autograft cusp configuration. Computed tomography angiography could become a tool for personalized planning of the Ross procedure.
Digital Technologies Tracking Active and Passive Data Collection in Depressive Disorders: Lessons Learned From a Case Series
Gardea‐Resendez, Manuel , Breitinger, Scott , Harper, Laura , Stoppel, Cynthia , Volety, Rama , Raman, Jeyakumar, Byun, Jin Soo, Langholm, Carsten , Zandi, Peter P. , Frye, Mark A. , Xiong, Ashley , Volety, Rama M, Gardea-Resendez, Manuel , Walker, Alex, Raman, Jeyakumar, Goes, Fernando , Torous, John Blake

Mayo Clinic

Journal of Psychiatric Practice | December 10, 2024 | Volume: 30 | Issue: 6 | Pages: 434-439

10.1097/pra.0000000000000820 | PMID 39655971 Get It

In this case series, we present several examples from participants (2 patients and 1 healthy control) of a 12-week pilot feasibility study to create a digital phenotype of depression (unipolar or bipolar) through active and passive data collection from a smartphone and a wearable device combined with routine clinical care for mood disorders. The selected cases represent real clinical examples that highlight the intrinsic challenges that should be expected when conducting similar studies, including appropriate health data privacy protection, clinical standardization, and interindividual differences in levels of engagement and acceptability of active and passive data collection (ie, self-reported, behavioral, cognitive, and physiological data), particularly with patient-generated data in mobile apps, digital proficiency habituation, and consistent use of wearable devices. In the context of the rapidly growing use of digital technologies in psychiatry, anticipating challenges for the integration of personal mobile devices and smartphone mental health apps as aides to track specific aspects of depressive disorders is critical for a clinically meaningful digital transformation of mood disorders care.
Nationwide Cross-Sectional Analysis of Mortality Trends in Patients with Sarcoidosis and Non-Ischemic Cardiovascular Disease—The Impact of Gender, Ethnicity, Geographical Location, and COVID-19 Pandemic
Ahmed, Raheel , Ahmed, Mushood , Khlidj, Yehya , Rehman, Obaid Ur , Al-Mukhtar, Laith, Khater, Noha Abou , Gardezi, Syed K M , Rashid, Muhammad, Collins, Peter L. , Jain, Hritvik , Ramphul, Kamleshun , Baig, Mudassar , Kouranos, Vasileios , Paray, Nitish Behary , Sharma, Rakesh , Rashid, Muhammad , Khurram Mustaq Gardezi, Syed , Kouranos, Vasilis , Sharma, Rakesh , Ahmed, Raheel , Khlidj, Yehya , Ahmed, Mushood , Chahal, C. Anwar A.

Mayo Clinic

Journal of Clinical Medicine | December 9, 2024 | Volume: 13 | Issue: 23 | Pages: 7463

10.3390/jcm13237463 | PMID 39685921 Get It

Background and Objectives: The epidemiological data regarding mortality rates of adults with sarcoidosis and non-ischemic cardiovascular disease (CVD) are limited. A retrospective observational analysis was conducted to identify trends and disparities related to sarcoidosis and non-ischemic cardiovascular disease mortality among the adult US population from 1999 to 2022. Methods: We used the Centers for Disease Control and Prevention (CDC) WONDER database to extract death certificate data for the adult US population (≥25 years). The age-adjusted mortality rates (AAMRs) per 100,000 persons were calculated, and annual percent changes (APCs) were determined using Joinpoint. Results: Between 1999 and 2022, 23,642 deaths were identified related to non-ischemic CVD + sarcoidosis. The overall AAMR increased from 0.2 (95% CI, 0.2 to 0.3) in 1999 to 0.5 (95% CI, 0.5 to 0.6) in 2022. Females had a higher AAMR than males (0.6 vs. 0.5). Non-Hispanic (NH) blacks had the highest AAMR, followed by NH whites and Hispanic or Latinos. The southern region had the highest AAMR (0.7: 95% CI, 0.6–0.7), followed by the Midwest (0.6, 95% CI, 0.54–0.669), the Northeast (0.5, 95% CI, 0.5 to 0.6), and the West (0.4; 95% CI, 0.3–0.4). Urban and rural areas had comparable mortality rates (0.5 vs. 0.6). People aged 65+ had the highest AAMRs. Conclusions: The overall mortality rates for non-ischemic CVD and sarcoidosis have increased in the US from 1999 to 2022. Females and NH blacks had higher AAMRs, while a minimal variation was observed based on geographical regions. Early diagnosis and prompt management are the keys to reducing the mortality burden of non-ischemic CVD plus sarcoidosis.
Weight loss with atogepant during the preventive treatment of migraine: A pooled analysis
Peterlin, B. Lee , Bond, Dale S. , Ferreira, Rosa De Abreu, Dabruzzo, Brett , Goadsby, Peter J. , Trugman, Joel M. , Dabruzzo, Brett , Goadsby, Peter J , Ailani, Jessica , Dodick, David W. , Liu, Yingyi , Smith, Jonathan H.

Mayo Clinic

Cephalalgia | December 9, 2024 | Volume: 44 | Issue: 12 | Pages: No page available

10.1177/03331024241299753 | PMID 39648629 Get It

Background Migraine is associated with obesity. These analyses evaluated weight change with atogepant used as a preventive migraine treatment. Methods Five atogepant clinical trials in adults with migraine (one phase 2b/3; four phase 3) were included: Three 12-week, randomized, placebo-controlled trials (episodic migraine: two; chronic migraine: one); one 40-week, open-label extension trial and one 52-week, standard care, randomized, long-term safety trial in episodic migraine. Change from baseline in body weight was measured. Results Mean baseline body mass indexes were 30.0–30.7 kg/m 2 (pooled episodic migraine [United States only]) and 25.0–25.5 kg/m 2 (chronic migraine [East Asia, Europe, and North America]). More participants treated with atogepant 60 mg once-daily compared to placebo experienced ≥7% weight loss at any time in the pooled episodic migraine placebo-controlled trials (4.9% vs. 2.8%), chronic migraine placebo-controlled trial (5.8% vs. 2.0%), and pooled open-label extension and long-term safety trials (24.0% vs.14.7% in standard care [long-term safety only]). In the placebo-controlled trials, weight loss with atogepant 60 mg once-daily was observed at week 2 (pooled episodic migraine: −0.32%; chronic migraine: −0.39%), increasing at week 12 (pooled episodic migraine: −1.02%; chronic migraine: −1.50%); compared to weight gain with placebo at week 12 (pooled episodic migraine: +0.49%; chronic migraine: +0.10%). In the long-term episodic migraine studies, weight loss with atogepant 60 mg once-daily was observed at week 4 (long-term safety: −0.42%; open-label extension: −0.76%), increasing at week 40 (long-term safety: −2.38%; open-label extension: −2.09%). Conclusion Atogepant was associated with modest dose- and duration-dependent weight loss. Trial registration ClinicalTrials.gov identifiers: NCT02848326 (CGP-MD-01); NCT03777059 (3101-301-002); NCT03700320 (long-term safety trial); NCT03939312 (open-label extension trial); NCT03855137 (3101-303-002).